GT Biopharma Inc (GTBP)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $7.67M
Last updated: Nov 17, 2026 at 4:42 PM ET
GT Biopharma Inc (GTBP) Statistics
GT Biopharma (GTBP) has a market cap of $7.67M. Its share count is up 28666.26% from a year earlier. It holds $9.92M more cash than debt, 129.42% of its market cap.
Total Valuation
| Market Cap | $7.67M |
|---|---|
| Latest price (Nov 17, 2026) | $3.18 |
Key Dates
The next earnings report is expected on Mar 1, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 1, 2027 (expected) |
|---|---|
| Last Earnings Date | Aug 14, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is down 86.18% over 52 weeks and trades 47.87% below its 50-day average.
| Beta (1Y) | 1.35 |
|---|---|
| 52-Week Change | -86.18% |
| 1-Month Change | -52.47% |
| 3-Month Change | -55.66% |
| 6-Month Change | -70.42% |
| 5-Year Change | -99.89% |
| Total Return (1Y) | -86.18% |
| Total Return (3Y CAGR) | -73.78% |
| Total Return (5Y CAGR) | -75.56% |
| Return vs SPY (1Y) | -92.15% |
| Max Drawdown (1Y) | -86.18% |
| Max Drawdown (3Y) | -98.42% |
| Sharpe Ratio (1Y) | -1.41 |
| Correlation with SPY (1Y) | 0.16 |
| 50-Day Average | $6.10 |
| 200-Day Average | $8.96 |
| 52-Week Range | $3.50 to $23.60 |
| RSI (14 Days) | 25.9 |
| Average Volume (20 Days) | 81.62K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 3.82x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 3.82x |
|---|---|
| Quick Ratio | 3.82x |
| Debt / Equity | 0.00x |
| Interest Coverage | -24.93x |
Returns and Efficiency
Return on equity is -434.61% and return on assets is -320.90% over the last 12 months.
| Return on Equity (ROE) | -434.61% |
|---|---|
| Return on Assets (ROA) | -320.90% |
| Return on Capital Employed (ROCE) | -420.08% |
| ROIC (5Y Average) | -37.33% |
Scores
GTBP has a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 2 of 9 |
|---|---|
| Piotroski Strength | Weak |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Operating Income | -$16.46M |
| Pretax Income | -$33.91M |
| Net Income | -$33.91M |
| EBIT | -$32.78M |
| Reported EPS (TTM) | -$3,051.50 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 73.79% of the $10.57M in total assets.
| Cash and Equivalents | $9.92M |
|---|---|
| Total Debt | $0 |
| Net Cash | $9.92M |
| Net Cash Per Share | $5.47 |
| Working Capital | $7.80M |
| Shareholder Equity | $7.80M |
| Book Value Per Share | $4.30 |
| Total Assets | $10.57M |
| Total Liabilities | $2.77M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$13.39M |
|---|---|
| FCF Per Share | -$6.50 |
Trailing 12 months through Sep 30, 2026.
Growth
| Book Value Per Share Growth (2Y CAGR) | -55.97% |
|---|---|
| Tangible Book Per Share Growth (2Y CAGR) | -55.97% |
Stock Splits
The last split was a 1-for-25 reverse split on Sep 8, 2026.
| Last Split Date | Sep 8, 2026 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:25 |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About GTBP
What is GTBP's market cap?
GT Biopharma has a market cap of $7.67M.
How many shares of GTBP are outstanding?
GT Biopharma has 1.81M shares outstanding. The count is up 28666.26% from a year earlier.
Does GTBP pay a dividend?
No. GT Biopharma does not pay a dividend.
How much debt does GTBP have?
GT Biopharma has $0 of total debt and $9.92M of cash and equivalents, a net cash position of $9.92M.
GTBP pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors